Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5) > Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5):447-57

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,311


eTOC

 

REVIEW  


Giornale Italiano di Dermatologia e Venereologia 2017 October;152(5):447-57

DOI: 10.23736/S0392-0488.17.05681-4

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

The management of moderate-to-severe chronic plaque psoriasis

Annalisa TONINI 1, Salvatore PANDURI 1, Angelo M. D’ ERME 1, 2, Francesca PAPADIA 1, Marco ROMANELLI 1, James G. KRUEGER 3, Andrea CHIRICOZZI 1

1 Department of Dermatology, University of Pisa, Pisa, Italy; 2 Unit of Dermatology, Livorno Hospital, Livorno, Italy; 3 The Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, USA


PDF  


Recent approval and marketization of novel treatments have widened the range of therapeutic opportunities for moderate-to-severe psoriasis. In the next years, this panorama will be further enlarged as many other agents, both oral small molecules and biologics, have passed phase III and are expected to be approved, and subsequently marketed, shortly. In spite of this array of therapeutic possibilities, there is still an unmet need for an appropriate treatment in a large number of cases. This review was aimed to describe general principles regarding the therapeutic approach to moderate-severe plaque psoriasis, providing an updated overview of the therapeutic armamentarium that is specifically available in Italy, drug prescriptibility, and some peculiar limitations for reimbursement defined by our National Health Care System.


KEY WORDS: Psoriasis - Apremilast - Therapeutics

inizio pagina

Publication History

Issue published online: September 12, 2017
Article first published online: May 23, 2017
Manuscript accepted: May 12, 2017
Manuscript received: May 5, 2017

Per citare questo articolo

Tonini A, Panduri S, D’Erme AM, Papadia F, Romanelli M, Krueger JG, et al. The management of moderate-to-severe chronic plaque psoriasis. G Ital Dermatol Venereol 2017;152:447-57. DOI: 10.23736/S0392-0488.17.05681-4

Corresponding author e-mail

andrea.chiricozzi@unipi.it